Pharma Q1 Earnings Review - Domestic Drives The Show; Margin Pressure May Persist In Near Term: Anand Rathi
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
Q1 FY22 sales growth for most pharma companies was driven by their India business.
Overall sales of the companies we cover grew 11.6% to Rs 168.7 billion.
India growth was much higher in Q1 (44.9%), ahead of the industry’s ~37% growth.
Challenges in the U.S. and the higher base in active pharma ingredient largely offset the benefits of India sales.
Ebitda slipped 2.5% to Rs 42.1 billion.
The Ebitda margin shrank 364 basis points to 25% from higher price erosion in the U.S., raw material price rises and normalised promotional expense.
Adjusted profit after tax declined 2.4% to Rs 27.8 billion.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.